{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:48:11Z","timestamp":1791924491474,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-COHO-0004"],"award-info":[{"award-number":["ANR-10-COHO-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.esmorw.2026.100789","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:44:30Z","timestamp":1791823470000},"page":"100789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoadjuvant versus adjuvant chemotherapy in luminal B-like breast cancer: a subset analysis of the CANTO study"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-9379","authenticated-orcid":false,"given":"T.","family":"Gaillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-3932","authenticated-orcid":false,"given":"P.","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-8576","authenticated-orcid":false,"given":"A.-L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bertaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cheymol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kaderbhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-7168","authenticated-orcid":false,"given":"F.","family":"Cherifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Di-Meglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Reyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Hamy-Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-4011","authenticated-orcid":false,"given":"E.","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9938","key":"10.1016\/j.esmorw.2026.100789_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100789_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100789_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000371","article-title":"Neoadjuvant treatment: the future of patients with breast cancer","volume":"3","author":"Reyal","year":"2018","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100789_bib4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4048\/jbc.2014.17.4.376","article-title":"Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients","volume":"17","author":"Luangdilok","year":"2014","journal-title":"J Breast Cancer"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100789_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100789_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/bjs.5894","article-title":"Neoadjuvant chemotherapy for operable breast cancer","volume":"94","author":"Mieog","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.esmorw.2026.100789_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fonc.2012.00125","article-title":"Breast cancer: from \u201cmaximum tolerable\u201d to \u201cminimum effective\u201d treatment","volume":"2","author":"Veronesi","year":"2012","journal-title":"Front Oncol"},{"issue":"9814","key":"10.1016\/j.esmorw.2026.100789_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100789_bib9","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100789_bib10","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100789_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100789_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmorw.2026.100789_bib13","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100789_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01)","volume":"38","author":"Lluch","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100789_bib15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.esmorw.2026.100789_bib16","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100789_bib17","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","article-title":"Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer","volume":"91","author":"Ring","year":"2004","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.esmorw.2026.100789_bib18","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","article-title":"Breast cancer molecular subtypes respond differently to preoperative chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100789_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","article-title":"Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy","volume":"170","author":"Haque","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100789_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000562","article-title":"UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)","volume":"4","author":"Vaz-Luis","year":"2019","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100789_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.esmorw.2026.100789_bib24","series-title":"Statistical Analysis of Epidemiologic Data","author":"Selvin","year":"2004"},{"key":"10.1016\/j.esmorw.2026.100789_bib48","series-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2010"},{"key":"10.1016\/j.esmorw.2026.100789_bib25","series-title":"R: A Language and Environment for Statistical Computing","year":"2023"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100789_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100789_bib27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ejso.2016.02.252","article-title":"Neoadjuvant chemotherapy in breast-conserving surgery\u2013consequences on margin status and excision volumes: a nationwide pathology study","volume":"42","author":"Volders","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100789_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.10741","article-title":"Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18","volume":"95","author":"Fisher","year":"2002","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.esmorw.2026.100789_bib29","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100789_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-016-3961-2","article-title":"BIRC5 (survivin): a pejorative prognostic marker in stage II\/III breast cancer with no response to neoadjuvant chemotherapy","volume":"159","author":"Hamy","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100789_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007279","article-title":"First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial","volume":"11","author":"De Caluwe","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmorw.2026.100789_bib32","article-title":"Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+\/HER2\u2013 breast cancer: results from the phase 3 KEYNOTE-756 study","volume":"200","author":"Cardoso","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100789_bib33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100789_bib34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamaoncol.2015.4508","article-title":"Time to surgery and breast cancer survival in the United States","volume":"2","author":"Bleicher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100789_bib35","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1245\/s10434-019-07566-7","article-title":"Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival: a National Cancer Database analysis","volume":"26","author":"Kupstas","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"28","key":"10.1016\/j.esmorw.2026.100789_bib36","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100789_bib37","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1177\/0962280215584401","article-title":"The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes","volume":"26","author":"Austin","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.esmorw.2026.100789_bib38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.radonc.2019.09.018","article-title":"Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancer","volume":"142","author":"Almahariq","year":"2020","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100789_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227256","article-title":"Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer","volume":"15","author":"Huang Bartlett","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100789_bib40","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.annonc.2023.04.002","article-title":"Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+\/HER2\u2212 early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+\/HER2\u2212 trial","volume":"34","author":"Gluz","year":"2023","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmorw.2026.100789_bib41","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2- early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.esmorw.2026.100789_bib42","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.2010.31.8469","article-title":"Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"29","author":"Mittendorf","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100789_bib43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100789_bib44","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","article-title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","volume":"29","author":"Cottu","year":"2018","journal-title":"Ann Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:16:10Z","timestamp":1791922570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":43,"alternative-id":["S2949820126001086"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100789","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant versus adjuvant chemotherapy in luminal B-like breast cancer: a subset analysis of the CANTO study","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100789"}}